United KingdomAustralia's Therapeutic Goods Administration (TGA) has issued a warning regarding certain GLP-1 receptor agonist (GLP-1 RA) drugs, such as Ozempic, Wegovy, and Mounjaro, linking them to a rare but severe eye disorder known as non-arteritic anterior ischaemic optic neuropathy (NAION), which can lead to blindness. This warning follows reports of 36 cases of NAION associated with these medications. While the TGA emphasizes that the condition is rare and that no effective treatment exists once it occurs, it advises patients to seek immediate medical attention if they experience sudden vision loss. However, the TGA does not recommend stopping the medication without consulting a healthcare provider. Experts note that while NAION is concerning, the benefits of these drugs in managing serious health conditions like diabetes and obesity are substantial.
Bias read (Center): The article presents a balanced view by discussing both the risks and benefits of the medications, citing expert opinions and regulatory actions without apparent bias toward either side.
